Navigation Links
Genoptix Announces the Addition of New Members to Board of Directors
Date:8/1/2008

CARLSBAD, Calif., Aug. 1 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, announced the election of Karin Eastham and Laurence R. McCarthy, Ph.D. to its Board of Directors, effective as of July 30, 2008. Ms. Eastham has been elected to serve as a Class I director of Genoptix until the 2011 Annual Meeting of Stockholders and will also serve on the Audit Committee of the Board of Directors. Dr. McCarthy has been elected to serve as a Class II director of Genoptix until the 2009 Annual Meeting of Stockholders and will also serve on the Compliance Committee of the Board of Directors.

"We look forward to the contributions of Ms. Eastham and Dr. McCarthy as members of the Genoptix Board of Directors. Each bring their individual expertise in their fields and personal style of leadership, adding diversity of opinion and further strengthening the leadership of the company as we move forward," said Dr. Tina Nova Bennett, president and CEO of Genoptix.

Karin Eastham has served as the Executive Vice President, Chief Operating Officer, and Trustee for the Burnham Institute for Medical Research since 2004. Prior to this, Ms. Eastham was the Senior Vice President of Finance and the Chief Financial Officer for Diversa Corporation. She has also served in similar senior level management roles at Combichem, Inc., Cytel Corporation and Boehringer Mannheim Diagnostics. She currently serves on the Boards of Directors for multiple life science companies including Illumina, Inc., and Amylin Pharmaceuticals, Inc. She also serves on the boards of Tercica, Inc. and SGX Pharmaceuticals, Inc., which have entered into definitive merger agreements pursuant to which such companies will be acquired by Ipsen, S.A. and Eli Lilly and Company, respectively, subject to various conditions including stockholder approval. Ms. Eastham earned her MBA in Finance and B.S. in Accounting from Indiana University and is a member of the American Institute of Certified Public Accountants and the California Society of Certified Public Accountants. Ms. Eastham is also a Certified Director.

Laurence R. McCarthy, Ph.D., is a Venture Partner with Ampersand Ventures and President of Scientific Technologies and Solutions, LLC. Dr. McCarthy was President, CEO, Chairman and CTO of Focus Diagnostics and later served as its CTO following the company's acquisition by Quest Diagnostics. Prior to this, he was President for the U.S. Diagnostics Division of Boehringer Mannheim and Vice President and General Manager and Vice President R&D for Becton Dickinson & Co. Dr. McCarthy's academic experience includes faculty positions at Johns Hopkins School of Medicine, University of North Carolina School of Medicine, and Cornell University School of Medicine, as well as serving as a Laboratory Director at the Memorial Sloan-Kettering Cancer Center and at the North Carolina Memorial Hospital. Dr. McCarthy received his Ph.D. in Microbiology from the University of New Hampshire and his B.S. in Biology from St. Anselm College.

These additions bring the total number of members serving on the Genoptix, Inc. board to nine. They join Genoptix, Inc. president and CEO Tina Nova Bennett, Ph.D., board chairman Andrew Senyei, M.D., Robert Curry, Ph.D., Timothy Buono, Michael Henos, Arda Minocherhomjee, Ph.D., and Thomas Waltz, M.D.

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community- based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Actual results may differ materially from those projected. Genoptix disclaims, however, any intent or obligations to update these forward-looking statements.


'/>"/>
SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008
2. Genoptix Reports Strong Financial Results for First Quarter 2008
3. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
4. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
5. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
6. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
7. Genoptix Announces Pricing of Secondary Public Offering
8. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
9. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
10. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
11. Genoptix, Inc. Announces Pricing for Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Technique, technique, technique – ... when either lifting weights for strength training and exercise or simply lifting heavy objects, ... , “Body position is everything,” Dr. Chang says. “Improper technique in lifting anything heavy ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a ... today that its iClinic V12.2 solution has achieved approval from National Center for ... PCMH 2017 standards which emphasize team-based care with a significant focus on the ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... Allegheny ... to open The Alexis Joy D’Achille Center for Women’s Behavioral Health at West ... available in western Pennsylvania for women suffering from pregnancy-related depression. Construction of the ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... Carolina have remained steady since 2009, according to a Workers Compensation Research Institute ... study Monitoring the North Carolina System: CompScope™ Benchmarks, 17th Edition looks ...
(Date:5/23/2017)... Rosa, California (PRWEB) , ... May 23, 2017 ... ... health management (PHM) technology and a 2017 Best in KLAS category winner, has ... advantageous market position to extend and enhance its technology platform and product offerings,” ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... CHICAGO , May 5, 2017  May is ... of one of the most important methods to prevent ... to the Centers for Disease Control and Prevention, undetected ... stroke. 1 Omron, the global leader in personal ... on the elimination of heart attack and stroke and ...
(Date:5/4/2017)... , May 4, 2017  Fortuna Fix Inc. (" ... to be the first to eliminate the need for embryonic ... cells to treat neurodegenerative diseases. Fortuna ... with Professor Michael Fehlings , MD, PhD; Father ... , MD, MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)... Clarius Mobile Health, a digital healthcare ... this week at the American Congress of Obstetricians ... San Diego, CA from May ... perfect tool for clinicians to easily confirm pregnancy, ... pregnancy-related complications like ectopic pregnancy and placenta previa," ...
Breaking Medicine Technology: